Increased 10-Year Prevalence of Huntington’s Disease in South Korea: An Analysis of Medical Expenditure Through the National Healthcare System
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background and Purpose This study aimed to determine the updated 10-year prevalence of Huntington’s disease (HD) in South Korea and the medical and economic burdens across the duration of the disease. Methods Data from the National Health Insurance database during 2010–2019 were analyzed. We identified HD cases using predefined criteria. Information on age at diagnosis, sex, and common nonneurological comorbidities were collected. We analyzed individual patterns of the use of medical services and yearly medical expenditure. Incidence rates, 10-year prevalence rates, and longitudinal medical expenditure changes were assessed. Results New patients with HD (average=152.10) were detected every year, with an annual incidence of 0.29 per 100,000. The estimated 10-year prevalence of HD was 2.2 per 100,000. The most common ages at the time of diagnosis were 50–59 years (23.3%). In 2019, 56.4% of patients with HD were followed-up at referral or general hospitals, and 32.2% were managed at longterm- care hospitals. The annual medical cost for an individual was KRW 6,569,341±895,097 (mean±SD) (mean≈USD 5,653). Medical expenditure was the highest in those aged 60–79 years, and lowest in those younger than 30 years. However, in all age groups, the annual medical expenditure was highest during the 9 years following a diagnosis. Conclusions This study found that the actual prevalence of HD in South Korea was higher than previously thought and that patients are in a situation with high medical expenditure that persists over time.
Abstract
Background and Purpose This study aimed to determine the updated 10-year prevalence of Huntington’s disease (HD) in South Korea and the medical and economic burdens across the duration of the disease. Methods Data from the National Health Insurance database during 2010–2019 were analyzed. We identified HD cases using predefined criteria. Information on age at diagnosis, sex, and common nonneurological comorbidities were collected. We analyzed individual patterns of the use of medical services and yearly medical expenditure. Incidence rates, 10-year prevalence rates, and longitudinal medical expenditure changes were assessed. Results New patients with HD (average=152.10) were detected every year, with an annual incidence of 0.29 per 100,000. The estimated 10-year prevalence of HD was 2.2 per 100,000. The most common ages at the time of diagnosis were 50–59 years (23.3%). In 2019, 56.4% of patients with HD were followed-up at referral or general hospitals, and 32.2% were managed at longterm- care hospitals. The annual medical cost for an individual was KRW 6,569,341±895,097 (mean±SD) (mean≈USD 5,653). Medical expenditure was the highest in those aged 60–79 years, and lowest in those younger than 30 years. However, in all age groups, the annual medical expenditure was highest during the 9 years following a diagnosis. Conclusions This study found that the actual prevalence of HD in South Korea was higher than previously thought and that patients are in a situation with high medical expenditure that persists over time.
참고문헌 (36)
- Pringsheim T, "The incidence and prevalence of Huntington’s disease : a systematic review and meta-analysis", Mov Disord, 27, pp.1083~1091 (2012)
- Bruzelius E, "Huntington’s disease in the United States : variation by demographic and socioeconomic factors", Mov Disord, 34, pp.858~865 (2019)
- Chang CM, "Huntington’s disease in Hong Kong Chinese : epidemiology and clinical picture", Clin Exp Neurol, 31, pp.43~51 (1994)
- Chen YY, "Nationwide population-based epidemiologic study of Huntington’s disease in Taiwan", Neuroepidemiology, 35, pp.250~254 (2010)
- Nakashima K, "Epidemiological and genetic studies of Huntington’s disease in the San-in area of Japan", Neuroepidemiology, 15, pp.126~131 (1996)
- Lee HS, "Two cases of probable Huntington’s disease", J Korean Neurol Assoc, 6, pp.289~294 (1988)
- Jeon BS, "Gene analysis in Huntington disease", J Korean Neurol Assoc, 14, pp.494~501 (1996)
- Kim HS, "Current status of Huntington’s disease in Korea : a nationwide survey and national registry analysis", J Mov Disord, 8, pp.14~20 (2015)
- Shin CW, "Preliminary analysis of Huntington’s disease in South Korea", J Huntingtons Dis, 2, pp.83~87 (2013)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- 김한준, "Survival of Korean Huntington’s Disease Patients", Journal Of Movement Disorders, 9(3), pp.166~170 (2016), 대한파킨슨병및이상운동질환학회
- Huntington Study Group, "Tetrabenazine as antichorea therapy in Huntington disease : a randomized controlled trial", Neurology, 66, pp.366~372 (2006)
- Mercy L, "Incidence of early-onset dementias in Cambridgeshire, United Kingdom", Neurology, 71, pp.1496~1499 (2008)
- Ramos-Arroyo MA, "Incidence and mutation rates of Huntington’s disease in Spain : experience of 9 years of direct genetic testing", J Neurol Neurosurg Psychiatry, 76, pp.337~342 (2005)
- Almqvist EW, "High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia", Clin Genet, 60, pp.198~205 (2001)
- McCusker EA, "Prevalence of Huntington disease in New South Wales in 1996", Med J Aust, 173, pp.187~190 (2000)
- Morrison PJ, "Accurate prevalence and uptake of testing for Huntington’s disease", Lancet Neurol, 9, pp.1147~ (2010)
- Shiwach RS, "Prevalence of Huntington’s disease in the Oxford region", Br J Psychiatry, 165, pp.414~415 (1994)
- Pavoni M, "Epidemiologic approach to Huntington’s disease in northern Italy(Ferrara area)", Neuroepidemiology, 9, pp.306~314 (1990)
- Alonso ME, "Clinical and genetic characteristics of Mexican Huntington’s disease patients", Mov Disord, 24, pp.2012~2015 (2009)
- Paradisi I, "Huntington disease mutation in Venezuela : age of onset, haplotype analyses and geographic aggregation", J Hum Genet, 53, pp.127~135 (2008)
- Ranganathan M, "Age of onset and behavioral manifestations in Huntington’s disease : an enroll-HD cohort analysis", Clin Genet, 99, pp.133~142 (2021)
- Squitieri F, "DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence", Hum Mol Genet, 3, pp.2103~2114 (1994)
- Kwa L, "Influence of age of onset on Huntington’s disease phenotype", Tremor Other Hyperkinet Mov(N Y), 10, pp.21~ (2020)
- Cheng HR, "Correlation between CCG polymorphisms and CAG repeats during germline transmission in Chinese patients with Huntington’s disease", Neurosci Bull, 36, pp.811~814 (2020)
- Rawlins MD, "The prevalence of Huntington’s disease", Neuroepidemiology, 46, pp.144~153 (2016)
- Ohlmeier C, "Epidemiology and health care utilization of patients suffering from Huntington’s disease in Germany : real world evidence based on German claims data", BMC Neurol, 19, pp.318~ (2019)
- Podolsky S, "Increased frequency of diabetes mellitus in patients with Huntington’s chorea", Lancet, 1, pp.1356~1358 (1972)
- Hu Y, "High prevalence of diabetes mellitus in a five-generation Chinese family with Huntington’s disease", J Alzheimers Dis, 40, pp.863~868 (2014)
- Adler V, "Role of redox potential and reactive oxygen species in stress signaling", Oncogene, 18, pp.6104~6111 (1999)
- Evans JL, "Oxidative stress and stress-activated signaling pathways : a unifying hypothesis of type 2 diabetes", Endocr Rev, 23, pp.599~622 (2002)
- Montojo MT, "Huntington’s disease and diabetes : chronological sequence of its association", J Huntingtons Dis, 6, pp.179~188 (2017)
- Sadagurski M, "IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease", J Clin Invest, 121, pp.4070~4081 (2011)
- Steventon JJ, "Hypertension, antihypertensive use and the delayed-onset of Huntington’s disease", Mov Disord, 35, pp.937~946 (2020)
- Abildtrup M, "Cardiac dysautonomia in Huntington’s disease", J Huntingtons Dis, 2, pp.251~261 (2013)
- Suh GH, "The economic costs of dementia in Korea, 2002", Int J Geriatr Psychiatry, 21, pp.722~728 (2006)